Efficacy and Safety of treatment with Levofloxacin for Community-acquired Pneumonia
Not Applicable
- Conditions
- Community-acquired pneumonia in adults
- Registration Number
- JPRN-UMIN000008677
- Lead Sponsor
- Second Division, Department of Internal Medicine, Hamamatsu university school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who took respiratory quinolones for current pneumonia. 2.Patients who are prohibited to take levofloxacin. 3.Patients with liver dysfunction AST:more than three times the upper limit of normal ALT:more than three times the upper limit of normal T-bil:more than three times the upper limit of normal 4.Patients witg renal dysfunction (Cre is over than 3.0mg/dl, or Ccr is less than 30 mL/min/1.73m2) 5.Patients who has disease of central nervous system and expected spasm. 6.Patient whom conducting of the examination doctor judged inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical effectiveness at seven days after the end of treatment.
- Secondary Outcome Measures
Name Time Method Clinical and bacteriological effectiveness at the end of treatment. mortality, hospitalization, adverse event.